Oncoscience

Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment

Dana C. Galván1, Anoop P. Ayyappan2, Brad A. Bryan3

1 Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA

2 Department of Radiology, Texas Tech University Health Sciences Center, El Paso, TX, USA

3 Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, USA

Correspondence to:

Brad A. Bryan, email:brad.bryan@ttuhsc.edu

Keywords: angiosarcoma; cardiac tumor; metastatic; propranolol; beta blocker

Received: May 15, 2018 Accepted: August 2, 2018 Published: October 11, 2018

Abstract

Angiosarcoma is the most common malignant cardiac tumor. Cardiac angiosarcoma is a highly lethal neoplasm that is largely resistant to conventional anti-cancer therapy. Mean survival of patients with cardiac angiosarcoma is only 4 months, and almost all patients will succumb to the disease within 1 year. The beta blocker propranolol is an emerging therapy against angiosarcoma. When combined with conventional therapies, propranolol increases progression free and overall survival in patients with this tumor type. It is currently unknown if propranolol is capable of showing anti-cancer efficacy as a single agent therapy. We report a case of a 61 year old woman diagnosed with primary cardiac angiosarcoma and liver and lung metastases. This patient chose to decline conventional therapy, and instead was prescribed the beta blocker propranolol as a single agent treatment. After 12 months, the mediastinal mass substantially debulked and decreased in size, and the metastatic nodules stabilized or resolved with no evidence of hyper-metabolic activity on PET-CT. This is the first reported data showing long term efficacy of the beta blocker propranolol as a single agent therapy against angiosarcoma.


PII: 472